After first getting unexpectedly stiff-armed by the FDA, Merck KGaA says that its app for the oral MS therapy cladribine has now been granted a priority review, putting it on track for a fourth-quarter decision. The German pharma company has been trailing Novartis recently in the race to the market with the world's first oral MS drug. An expert panel has already voted to endorse Novartis' Gilenia. Story